Two-thirds of the patient and consumer organisations working with the European Medicines Agency (EMA) received partial or significant funding from pharmaceutical manufacturers and/or industry associations, which suggests that the pharmaceutical industry is the prevalent sponsor of the patient voice at the EMA.

Fewer than half of the 23 organisations complied with EMA financial reporting guidelines. The EMA appears to have failed in the monitoring and enforcement its guidelines on financial transparency.

These and other main findings are reported in HAI Europe’s recent survey on levels of financial disclosure and transparency among patient and consumer organisations at the European Medicines Agency (EMA).

Read the Research Article and Factsheet on our website